A team at Massachusetts General Hospital led by Harvard Medical School physician-scientists has for the second time successfully transplanted a genetically edited pig kidney into a living person. The team performed the first surgery of its kind in the world in March 2024.

FDA clears United Therapeutics for human trials of pig-to-human kidney transplants. Trial involves gene-edited pig kidneys for patients with end-stage renal disease. Study aims to provide alternative for 500,000 Americans on dialysis.

A Mass General Hospital surgical team has completed its second pig-to-human kidney transplant, less than a year after the hospital performed the world’s first such surgery.

Towana Looney, a woman from Alabama who last year became the third person to undergo a pig kidney transplant, is reportedly still recovering well after her surgery. Having now passed two months since the operation,

The U.S. Food and Drug Administration (FDA) has approved the first-ever clinical trials testing pig kidney transplants in people with kidney failure, marking a major step forward in cross-species transplantation.

The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a long wait for human organ transplants.